MBRX
NASDAQMoleculin Biotech Inc.
Price$2.40+0.02 (+0.63%)
2026-03-042026-06-05
News · 26 weeks62-33%
2025-12-142026-06-07
Mix3490d
- SEC Filings19(56%)
- Other13(38%)
- Dividends2(6%)
Latest news
25 items- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLSurveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel survey of payers shows strong support for Annamycin filling a significant unmet need HOUSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML). The research demonstrated strong physician interest in Annamycin, with oncologists reporting an average likelihood-to-prescribe score of 6 out of 7.
- PRMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment- Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Klemp discussed the Company's recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsIndependent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced new data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting further reinforcing the differentiated cardiac safety profile of its lead drug candidate, Annamycin (also known as "L-Annamycin" or "naxtarubicin"). The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for AnnamycinHOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as "L-Annamycin" or "naxtarubicin"), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. Access the abstract here. The abstract, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," will be presented in a poster session focused on Symptom Science and Palliative Care. Presentation Details: Sessi
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialEarly blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial Enrollment in MIRACLE trial continues to advance on pace with 90th subject expected in Q3 2026 HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. "With enrollment now surpassing the first interim analysis threshold in the MIRACLE trial, we are just weeks away from beginning wh
- SECSEC Form 10-Q filed by Moleculin Biotech Inc.10-Q - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksPreliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30, 2026Program targets high-unmet-need AML population, including R/R Venetoclax subjects Recruitment of Part A continues to the target 90 subjects in Q3 2026 with 56 or 62% subjects recruited and randomizedContinued absence of cardiotoxicity and high efficacy expected to position Annamycin as a "significant advancement" in AML treatment HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it is approaching the first unb
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline LimitsPooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline use in heavily pretreated R/R AML HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced the publication of an abstract at the European Hematology Association (EHA) 2026 Congress highlighting the cardiac safety profile of Annamycin (or as known in scientific journals "L-Annamycin"), the Company's next-generation anthracycline currently in late-stage development for the treatment of relapsed/refractor
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinSolid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin. The newly granted patent (No. 40073244), titled "Method of Reconstituting Liposomal Annamycin," extends protection through June 25, 2040, further reinforcing Moleculin's long-term global exclusivity strategy. The invention is jointly owned with The University of Texas System. This patent r
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems (p<0.001) Significantly higher tumor and pancreatic tissue accumulation than doxorubicin (p<0.0001), providing a mechanistic basis for Annamycin's activity where traditional anthracyclines have historically failed Induced infiltration of CD8+ and CD4+ T cells, suggesting potential to convert immunologically "cold" pancreatic tumors into responders and supporting future combinations with chec
- PRMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingHOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. The abstract, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," will be presented in a poster session focused on Symptom Science and Palliative Care. Presentation Details: Session Type: Poster Session - Symptom Science and Palliative CarePresentation Date and Time: Ma
- SECMoleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form EFFECT filed by Moleculin Biotech Inc.EFFECT - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Moleculin Biotech Inc.10-K/A - Moleculin Biotech, Inc. (0001659617) (Filer)
- SECSEC Form 424B3 filed by Moleculin Biotech Inc.424B3 - Moleculin Biotech, Inc. (0001659617) (Filer)
- PRMoleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic ProfileAccess the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. In this segment, Mr. Klemp highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. Annamycin was specifically designed to avoid cardiac damage, and has demonstrated this advantage across preclinical and clinical studies. This non-cardiotoxic profile could expand treatment opt
MBRX FAQ
7 questionsWhat does Moleculin Biotech Inc. do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies...Where does MBRX stock trade?
Moleculin Biotech Inc. (MBRX) is listed on NASDAQ.What sector and industry is MBRX in?
Moleculin Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Moleculin Biotech Inc. go public?
Moleculin Biotech Inc. (MBRX) completed its IPO in 2016.What are analysts saying about MBRX?
Moleculin Biotech Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $400.00 price target on 2025-06-09. Recent price targets range from $400.00 to $1400.00.What companies are similar to MBRX?
Notable peers in the same industry include KRYS (Krystal Biotech Inc.), BBI (Brickell Biotech Inc.), PMCB (PharmaCyte Biotech Inc.). Compare MBRX side-by-side with any of them on Quantisnow.How can I track MBRX on Quantisnow?
Quantisnow aggregates Moleculin Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MBRX to receive live email and push alerts on every new disclosure.